Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00749632 · ClinicalTrials.gov registry record · Phase 2

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

A Phase 2 study of Urinary Incontinence, Urge, sponsored by FemmePharma Global Healthcare.

Completed
Registry status
Phase 2
Development phase
45
Enrollment target
2
Study locations

NCT00749632 is a Phase 2 study of Urinary Incontinence, Urge that has completed, run by FemmePharma Global Healthcare. The registered enrollment target is 45 participants, below the 153-participant average among 9 other Urinary Incontinence, Urge trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00749632, a Phase 2 study of Urinary Incontinence, Urge, has completed, sponsored by FemmePharma Global Healthcare.

COMPLETED
Registry status
Phase 2
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

Conditions Studied

Interventions

  • DRUG oxybutynin

Study Locations (2)

Maryland

  • SNBL Clinical Pharmacology Center - Baltimore

New Jersey

  • Advanced Biomedical Research - Hackensack

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-07
Est. Completion 2008-10
Phase Phase 2

Sponsor

FemmePharma Global Healthcare

3 total trials

What the Registry Record Tells You About NCT00749632

The ClinicalTrials.gov registry entry for NCT00749632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 9 other Urinary Incontinence, Urge trials with a reported enrollment target (71% lower). The listed sponsor is FemmePharma Global Healthcare, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Incontinence, Urge appearing as the primary indexed condition, and to 1 intervention - of which oxybutynin is the first listed.

NCT00749632 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, New Jersey.

Frequently Asked Questions

What is clinical trial NCT00749632 about?

NCT00749632 is a clinical study titled "A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence". The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

What is the current status of trial NCT00749632?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-07. Estimated completion is 2008-10.

What conditions does trial NCT00749632 study?

This clinical trial studies the following conditions: Urinary Incontinence, Urge.

What interventions are being tested in trial NCT00749632?

The interventions under investigation include: oxybutynin (DRUG).

Who is sponsoring clinical trial NCT00749632?

This trial is sponsored by FemmePharma Global Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00749632 being conducted?

This trial has 2 study locations across Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence, Urge

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.